Bromazepam

證據等級: L5

預測適應症: 1 個

Bromazepam: From Anxiolytic Use to Migraine Disorder

One-Sentence Summary

Bromazepam is a benzodiazepine-class anxiolytic, widely used for the management of anxiety disorders. The TxGNN model predicts it may be effective for Migraine Disorder, but currently only 1 indirectly related clinical trial and no publications support this direction, making the evidence base extremely thin.

Quick Overview

Item	Content
Original Indication	Anxiolytic (benzodiazepine class; specific approved indication text not available in data source)
Predicted New Indication	Migraine Disorder
TxGNN Prediction Score	99.06%
Evidence Level	L5 (Model prediction only, no direct studies)
Malaysia Market Status	✓ Marketed
Number of Registrations	2
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on known pharmacology, bromazepam is a positive allosteric modulator of the GABA-A receptor belonging to the benzodiazepine class. Its primary clinical use is for the short-term management of anxiety and tension states. The GABAergic system plays a modulatory — though not central — role in migraine pathophysiology.

The theoretical link between bromazepam and migraine is indirect: anxiety and psychological stress are well-established migraine triggers, and an anxiolytic agent could hypothetically reduce migraine frequency by attenuating upstream trigger factors. However, this represents symptom-trigger management rather than direct intervention in the migraine disease pathway. Mainstream migraine-specific therapies (triptans, CGRP inhibitors, anti-epileptic drugs) target entirely different mechanisms — serotonergic, calcitonin gene-related peptide, or voltage-gated ion channel pathways — none of which primarily involve GABA-A modulation.

Overall, while the TxGNN prediction score is high (99.06%), the mechanistic link is speculative. The absence of any direct clinical or preclinical evidence specifically investigating bromazepam as a migraine treatment means this prediction should be interpreted with caution and classified as hypothesis-generating only.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04410536	Phase 4	Completed	25	Home-withdrawal programme combined with behavioural therapy for Medication Overuse Headache (MOH) during COVID-19. Bromazepam likely served as an anxiolytic adjunct during withdrawal, not as a primary migraine treatment. Relevance to bromazepam–migraine repurposing is low (Grade C).

Note: The single identified trial does not constitute direct evidence for bromazepam as a migraine treatment. The trial investigated withdrawal strategies for medication overuse headache — a clinically distinct entity from primary migraine — and bromazepam’s role was ancillary anxiety management, not migraine-directed therapy.

Literature Evidence

Currently no related literature available.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(Not available)	(Not available)	(Not available)	(Not available)
(Not available)	(Not available)	(Not available)	(Not available)

Note: Two registrations are recorded in the database, but detailed licence information (authorization numbers, product names, dosage forms, and approved indications) was not available in the current data extract.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not available in the current evidence pack. As a benzodiazepine, standard class-level concerns include dependence risk, CNS depression, respiratory depression (especially in combination with opioids or alcohol), and withdrawal syndrome upon abrupt discontinuation.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN prediction score (99.06%), the evidence base is critically insufficient. The only identified clinical trial (NCT04410536) is indirectly related — it investigates medication overuse headache withdrawal, not bromazepam as a migraine treatment — and no published literature directly supports this repurposing hypothesis. The mechanistic link between GABAergic anxiolysis and migraine pathophysiology is speculative at best. Additionally, as a controlled substance with dependence potential, chronic use of a benzodiazepine for a recurring condition like migraine raises significant safety and regulatory concerns.

To proceed, the following is needed:

Detailed mechanism of action data (MOA) from DrugBank to assess pharmacological plausibility
Package insert safety data (warnings, contraindications) from the Malaysian regulatory authority
Preclinical studies specifically examining GABA-A modulation in migraine models
At minimum one Phase 2 proof-of-concept trial evaluating bromazepam (or a closely related benzodiazepine) for migraine prophylaxis or acute treatment
Risk-benefit analysis addressing long-term benzodiazepine use in a chronic episodic condition
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.